




Instance: composition-en-ff7e41e620a058f62e199d7b81a017a6
InstanceOf: CompositionUvEpi
Title: "Composition for resolor Package Leaflet"
Description:  "Composition for resolor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/581/001 (28 tablets)"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpff7e41e620a058f62e199d7b81a017a6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - resolor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Resolor is and what it is used for</li>
<li>What you need to know before you take Resolor</li>
<li>How to take Resolor</li>
<li>Possible side effects</li>
<li>How to store Resolor</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What resolor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What resolor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Resolor contains the active substance prucalopride.
Resolor belongs to a group of gut motility enhancing medicines (gastrointestinal prokinetics). It acts 
on the muscle wall of the gut, helping to restore the normal functioning of the bowel. Resolor is used 
for the treatment of chronic constipation in adults in whom laxatives do not work well enough.
Not for use in children and adolescents younger than 18 years.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take Resolor:</h2>
<p>if you are allergic to prucalopride or any of the other ingredients of this medicine (listed in 
section 6).
-
if you are on renal dialysis,
-
if you suffer from perforation or obstruction of the gut wall, severe inflammation of the 
intestinal tract, such as Crohn s disease, ulcerative colitis or toxic megacolon/megarectum.
Warnings and precautions
Talk to your doctor before taking Resolor.
Take special care with Resolor and tell your doctor if you:
-
suffer from severe kidney disease,
-
suffer from severe liver disease,
-
are currently under supervision by a doctor for a serious medical problem such as lung or heart 
disease, nervous system or mental health problems, cancer, AIDS or a hormonal disorder.
If you have very bad diarrhoea, the contraceptive pill may not work properly and the use of an extra 
method of contraception is recommended. See the instructions in the patient leaflet of the 
contraceptive pill you are taking.
Other medicines and Resolor
Tell your doctor if you are taking, or have recently taken, or might take any other medicines.
Resolor with food and drink
Resolor can be taken with or without food and drinks, at any time of the day.
Pregnancy and breast-feeding
Resolor is not recommended for use during pregnancy.
-
Tell your doctor if you are pregnant or planning to become pregnant.
-
Use a reliable method of contraception while you re taking Resolor, to prevent pregnancy.
-
If you do become pregnant during treatment with Resolor, tell your doctor.
When breast-feeding, prucalopride can pass into breast milk. Breast-feeding is not recommended 
during treatment with Resolor. Talk to your doctor about this.
Ask your doctor for advice before taking any medicine.
Driving and using machines
Resolor is unlikely to affect your ability to drive or use machines. However, sometimes Resolor may 
cause dizziness and tiredness, especially on the first day of treatment, and this may have an effect on 
driving and use of machines.
Resolor contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine.</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as described in this leaflet or as your doctor has told you. Check 
with your doctor or pharmacist if you are not sure. Take Resolor every day for as long as your doctor 
prescribes it.
The doctor may want to reassess your condition and the benefit of continued treatment after the first 
4 weeks and thereafter at regular intervals.
The usual dose of Resolor for most patients is one 2 mg tablet once a day.
If you are older than 65 years or have severe liver disease, the starting dose is one 1 mg tablet once a 
day, which your doctor may increase to 2 mg once a day if needed.
Your doctor may also recommend a lower dose of one 1 mg tablet daily if you have severe kidney
disease.
Taking a higher dose than recommended will not make the product work better.
Resolor is only for adults and should not be taken by children and adolescents up to 18 years.
If you take more Resolor than you should
It is important to keep to the dose as prescribed by your doctor. If you have taken more Resolor than 
you should, it is possible that you will get diarrhoea, headache and/or nausea. In case of diarrhoea, 
make sure that you drink enough water.
If you forget to take Resolor
Do not take a double dose to make up for a forgotten tablet. Just take your next dose at the usual time.
If you stop taking Resolor
If you stop taking Resolor, your constipation symptoms may come back again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side 
effects mostly occur at the start of treatment and usually disappear within a few days with continued 
treatment.
The following side effects have been reported very commonly (may affect more than 1 in 10 people): 
headache, feeling sick, diarrhoea and abdominal pain.
The following side effects have been reported commonly (may affect up to 1 in 10 people): decreased 
appetite, dizziness, vomiting, disturbed digestion (dyspepsia), windiness, abnormal bowel sounds, 
tiredness.
The following uncommon side effects have also been seen (may affect up to 1 in 100 people): tremors, 
pounding heart, rectal bleeding, increase in frequency of passing urine (pollakiuria), fever and feeling 
unwell. If pounding heart occurs, please tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of
this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The 
expiry date refers to the last day of that month.
Store in the original blister package in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Resolor contains
The active substance is prucalopride.
One film-coated tablet of Resolor 1 mg contains 1 mg prucalopride (as succinate).
One film-coated tablet of Resolor 2 mg contains 2 mg prucalopride (as succinate).
The other ingredients are:
Lactose monohydrate (see section 2), microcrystalline cellulose, colloidal silicon dioxide, magnesium 
stearate, hypromellose, triacetin, titanium dioxide (E171), macrogol. The 2 mg tablet also contains 
iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminium lake (E132).
What Resolor looks like and contents of the pack
Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked  PRU 1  on one 
side.
Resolor 2 mg film-coated tablets are pink round shaped tablets marked  PRU 2  on one side.
Resolor is provided in aluminium/aluminium perforated unit dose blister (calendar marked) containing 
7 tablets. Each pack contains 7x1, 14x1, 28x1 or 84x1 film-coated tablets.
Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HWIreland
Manufacturer
Sanico NV
Veedijk B-2300 Turnhout
Belgium
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel.: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
Drugsales Ltd
Tel: +356 21419safety@drugsalesltd.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>akeda    . .
T : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
Espa a
Takeda Farmac utica Espa a S.A.
Tel: +34 917 90 42 medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062medinfoEMEA@takeda.com
France
Takeda France SAS
T l: + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Takeda Farmac uticos Portugal, Lda.
Tel: + 351 21 120 1medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>A.POTAMITIS MEDICARE LTD
 : +357 22583a.potamitismedicare@cytanet.com.cy
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in . 
Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-ff7e41e620a058f62e199d7b81a017a6
InstanceOf: CompositionUvEpi
Title: "Composition for resolor Package Leaflet"
Description:  "Composition for resolor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/581/001 (28 tablets)"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpff7e41e620a058f62e199d7b81a017a6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - resolor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Resolor
3. Sådan skal du tage Resolor
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What resolor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What resolor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Resolor indeholder det aktive stof prucaloprid.
Resolor tilhører en gruppe lægemidler, der øger tarmbevægelserne (gastrointestinale prokinetika). Det
virker på tarmens muskelvæg og bidrager til at genskabe tarmens normale funktion. Resolor anvendes 
til behandling af kronisk forstoppelse hos voksne, hvor afføringsmidler ikke virker godt nok.
Bør ikke anvendes til børn og unge under 18 år.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Resolor:</h2>
<p>hvis du er allergisk over for prucaloprid eller et af de øvrige indholdsstoffer i Resolor (angivet i 
punkt 6).
-
hvis du er i dialyse
-
hvis du lider af perforation eller tillukning af tarmvæggen eller svær betændelse i tarmkanalen
såsom Crohns sygdom, ulcerøs colitis (sårdannelse og betændelse i tyktarmen) eller toksisk 
megakolon/megarektum (kraftig udvidelse af tyktarmen/endetarmen).
Advarsler og forsigtighedsregler
Kontakt lægen, før du tager Resolor.
Vær ekstra forsigtig med at bruge Resolor og fortæl det til lægen:
-
hvis du lider af svær nyresygdom
-
hvis du lider af svær leversygdom
-
hvis du i øjeblikket går til kontrol hos en læge på grund af en alvorlig sygdom såsom lunge-
eller hjertesygdom, problemer med nervesystemet eller psykiske problemer, kræft, aids eller 
hormonforstyrrelser.
32
Hvis du lider af meget slem diarré, virker dine p-piller muligvis ikke korrekt, og du anbefales derfor at 
bruge et ekstra præventionsmiddel. Se oplysningerne i indlægssedlen for den p-pille, som du bruger.
Brug af anden medicin sammen med Resolor
Fortæl altid lægen eller på apoteket, hvis du bruger anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler og vitaminer og mineraler.
Brug af Resolor sammen med mad og drikke
Resolor kan tages sammen med eller uden mad og drikke når som helst i løbet af dagen.
Graviditet og amning
Resolor bør ikke anvendes under graviditet.

Fortæl det til lægen, hvis du er gravid eller planlægger at blive gravid.

Anvend en sikker præventionsmetode, mens du tager Resolor, for at undgå graviditet.

Hvis du bliver gravid under behandlingen med Resolor, skal du fortælle det til lægen.
Prucaloprid kan udskilles i mælken ved amning. Amning anbefales ikke under behandling med 
Resolor. Tal med lægen om dette.
Spørg din læge eller apoteket til råds, inden du tager nogen form for medicin.
Trafik- og arbejdssikkerhed
Det er usandsynligt, at Resolor påvirker din evne til at færdes sikkert i trafikken og betjene maskiner.
Resolor kan dog forårsage svimmelhed og træthed, især på den første dag af behandlingen, og dette 
kan påvirke trafik- og arbejdssikkerheden.
Resolor indeholder lactose
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter.</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid dette lægemiddel nøjagtigt som beskrevet i denne indlægsseddel eller efter lægens anvisning.
Er du i tvivl, så spørg lægen eller på apoteket. Tag Resolor hver dag i så lang tid, som din læge har 
ordineret.
Lægen vil muligvis undersøge din sygdom og fordelen ved forlænget behandling på ny efter de første 
4 uger og derefter med regelmæssige intervaller.
Den sædvanlige dosis Resolor til de fleste patienter er én 2 mg-tablet én gang dagligt.
Hvis du er over 65 år, eller hvis du har en alvorlig leversygdom, er startdosis én 1 mg-tablet én gang 
dagligt. Din læge kan øge dosis til 2 mg én gang dagligt efter behov.
Din læge kan også anbefale en lavere dosis på én 1 mg-tablet én gang dagligt, hvis du lider af en svær 
nyresygdom.
Indtagelse af en højere dosis end anbefalet får ikke medicinen til at virke bedre.
Resolor er kun til voksne og bør ikke tages af børn og unge under 18 år.
Hvis du har taget for mange Resolor 
Det er vigtigt, at du tager præcis den dosis, som din læge har ordineret. Hvis du har taget for mange 
Resolor-tabletter, er det muligt, at du får diarré, hovedpine og/eller kvalme. I tilfælde af diarré skal du 
sørge for at drikke rigeligt vand.
33
Hvis du har glemt at tage Resolor
Du må ikke tage en dobbeltdosis som erstatning for den glemte tablet. Tag blot den næste dosis til 
sædvanlig tid.
Hvis du holder op med at tage Resolor
Hvis du holder op med at tage Resolor, kan symptomerne på forstoppelse komme igen.
Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Bivirkningerne optræder især i starten af behandlingen og forsvinder typisk inden for nogle få dage 
ved fortsat behandling.
Følgende meget almindelige bivirkninger er blevet indberettet (kan forekomme hos flere end 1 ud af 
10 personer): hovedpine, kvalme, diarré og mavesmerter.
Følgende almindelige bivirkninger er blevet rapporteret (kan forekomme hos op til 1 ud af personer): nedsat appetit, svimmelhed, opkastning, fordøjelsesforstyrrelser (dyspepsi), luft i maven, 
unormale tarmlyde, træthed.
Følgende ikke almindelige bivirkninger er også set (kan forekomme hos op til 1 ud af 100 personer): 
rystelser, hjertebanken, blødning fra endetarmen, hyppig vandladning (pollakisuri), feber og 
utilpashed. Hvis du får kraftig hjertebanken, skal du sige det til din læge.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført 
i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store resolor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store resolor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn.
Brug ikke dette lægemiddel efter den udløbsdato, der står på blisterkortet og æsken efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned.
Opbevares i det originale blisterkort for at beskytte mod fugt. 
Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Resolor indeholder:
Aktivt stof: prucaloprid.
Én filmovertrukken tablet Resolor 1 mg indeholder 1 mg prucaloprid (som succinat).
Én filmovertrukken tablet Resolor 2 mg indeholder 2 mg prucaloprid (som succinat).
34
Øvrige indholdsstoffer:
Lactosemonohydrat (se afsnit 2), mikrokrystallinsk cellulose, kolloid silica, magnesiumstearat, 
hypromellose, triacetin, titaniumdioxid (E 171) og macrogol. 2 mg-tabletten indeholder også rødt
jernoxid (E 172), gult jernoxid (E 172) og indigocarmin aluminium lake (E132).
Udseende og pakningsstørrelser
Resolor 1 mg filmovertrukne tabletter er hvide til råhvide, runde tabletter mærket med ’PRU 1’ på den 
ene side.
Resolor 2 mg filmovertrukne tabletter er lyserøde, runde tabletter mærket med ’PRU 2’ på den ene 
side.
Resolor fås i aluminium/aluminium perforerede enkeltdosisblisterkort (mærket med ugedagene) 
indeholdende 7 tabletter. Hver pakning indeholder 7 x 1, 14 x 1, 28 x 1 eller 84 x 1 filmovertrukne 
tabletter.
Ikke alle pakningsstørrelser er nødvendigvis markedsført i dit land.
Indehaver af markedsføringstilladelsen
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HW68
Irland
Fremstiller
Sanico NV
Veedijk 59
B-2300 Turnhout
Belgien
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Takeda Belgium NV
Tél/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com
България
Такеда България ЕООД
Тел.: +359 2 958 27 36
medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com
Česká republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com
Magyarország
Takeda Pharma Kft.
Tel.: +36 1 270 7030
medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 10
medinfoEMEA@takeda.com
Malta
Drugsales Ltd
Tel: +356 21419070
safety@drugsalesltd.com
35
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 669
medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com
Ελλάδα
Τakeda ΕΛΛΑΣ Α.Ε.
Tηλ: +30 210 6387800
medinfoEMEA@takeda.com
Österreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
España
Takeda Farmacéutica España S.A.
Tel: +34 917 90 42 22
medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062447
medinfoEMEA@takeda.com
France
Takeda France SAS
Tél: + 33 1 40 67 33 00
medinfoEMEA@takeda.com
Portugal
Takeda Farmacêuticos Portugal, Lda.
Tel: + 351 21 120 1457
medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com
România
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska družba d.o.o.
Tel: + 386 (0) 59 082 480
medinfoEMEA@takeda.com
Ísland
Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com
Slovenská republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com
Κύπρος
A.POTAMITIS MEDICARE LTD
Τηλ: +357 22583333
a.potamitismedicare@cytanet.com.cy
Sverige
Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840082
medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 902
medinfoEMEA@takeda.com
Denne indlægsseddel blev senest ændret .
36
Du kan finde yderligere information om Resolor på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu/.</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-ff7e41e620a058f62e199d7b81a017a6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for resolor Package Leaflet for language en"
Description: "ePI document Bundle for resolor Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ff7e41e620a058f62e199d7b81a017a6"
* entry[0].resource = composition-en-ff7e41e620a058f62e199d7b81a017a6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpff7e41e620a058f62e199d7b81a017a6"
* entry[=].resource = mpff7e41e620a058f62e199d7b81a017a6
                            
                    
Instance: bundlepackageleaflet-da-ff7e41e620a058f62e199d7b81a017a6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for resolor Package Leaflet for language da"
Description: "ePI document Bundle for resolor Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ff7e41e620a058f62e199d7b81a017a6"
* entry[0].resource = composition-da-ff7e41e620a058f62e199d7b81a017a6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpff7e41e620a058f62e199d7b81a017a6"
* entry[=].resource = mpff7e41e620a058f62e199d7b81a017a6
                            
                    



Instance: mpff7e41e620a058f62e199d7b81a017a6
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Resolor 1 mg film-coated tablets."
Description: "Resolor 1 mg film-coated tablets."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/581/001 (28 tablets)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Resolor 1 mg film-coated tablets."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ff7e41e620a058f62e199d7b81a017a6ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "resolor"

* status = #current
* mode = #working

* title = "List of all ePIs associated with resolor"

* subject = Reference(mpff7e41e620a058f62e199d7b81a017a6)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#resolor "resolor"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ff7e41e620a058f62e199d7b81a017a6) // resolor en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ff7e41e620a058f62e199d7b81a017a6) // resolor da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-ff7e41e620a058f62e199d7b81a017a6
InstanceOf: List

* insert ff7e41e620a058f62e199d7b81a017a6ListRuleset
    